David Kendal Stevenson, MD
Neonatal-Perinatal Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Stevenson’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G32668 · Current
Licensed to practise in California · since 1976 · expires 2027-03-31 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Neonatal-Perinatal Medicine
Money from drug and device companies
$1,342 in 2019
A payment is not proof that care is biased.
| Soleno Therapeutics | Diazoxide Choline Controlled Release (Dccr) | $1,342 | 2 payments
|
See all 2 published payments
| Soleno Therapeutics | Meals · 2019-04-15 | Diazoxide Choline Controlled Release (Dccr) | $176 |
| Soleno Therapeutics | Travel · 2019-04-15 | Diazoxide Choline Controlled Release (Dccr) | $1,166 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Soleno Therapeutics, Inc. · An Open-Label Study of Dccr (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome · 2025 | Their institution | $192,450 |
| Soleno Therapeutics, Inc. · An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With A Double-Blind, Placebo-Controlled, Randomized Withdrawal Period · 2025 | Their institution | $53,632 |
Professional record
- NPI
- 1558403790
- Licence
- CA G32668California G32668: Current · expires 2027-03-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080N0001X (2080N0001X); Pediatrics (208000000X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2007-02-13
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 750 Welch Rd, Palo Alto, CA, 94304